Ulcerative Colitis Flare
Conditions
Brief summary
The investigators intend to screen for new donors, given that there may a donor effect (PubMed ID: 25857665), with some donors not inducing remission in any patient whilst others inducing remission in 20-40% of cases. It is important to give UC patients participating in RCTs stool that has been demonstrated to be effective in some patients. We therefore propose to conduct an open label study in patients with active UC to ensure new donors are effective at inducing remission in some patients. Patients that have FMT will relapse within 18 months (PubMed ID: 25857665) although further FMT therapy induces remission so it is possible that maintenance FMT will result in long term remission, but this needs evaluation. We will therefore follow UC patients that have responded to FMT long term in this open label study.
Detailed description
This is an open label study with all UC patients receiving FMT. Up to 200 patients with active UC will be recruited to the study.
Interventions
Patients will come once a week for FMT for 8 weeks. FMT is the administration of the supernatant component of stool and water mixture from a healthy relative or an unrelated donor. The donor's stool and blood is rigorously screened to exclude known communicable diseases. Those that achieve remission with FMT will have the option of continuing FMT once per month for 3 years
Sponsors
Canadian Institutes of Health Research (CIHR)
Hamilton Health Sciences Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is an open label study with all UC patients receiving FMT.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18 or over 2. Active UC defined as a Mayo score (7) \>3 3. A Mayo endoscopic score (7) \>0 4. Females of child-bearing potential must be willing and able to use acceptable contraception as per Appendix III. II. b. Toxicity section of the Health Canada Guidance
Exclusion criteria
1. Participating in another intervention study for UC 2. Unable to give informed consent 3. Severe comorbid medical illness 4. Severe UC requiring hospitalization. 5. Increase in medical therapy for UC in the last 12 weeks. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNF therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will also be permitted provided the dose of steroid is not increased again. Stable intake of probiotic therapy also permitted. 6. Antibiotic therapy in the last 30 days. 7. Pregnant women. 8. Patients with clinically significant hepatic dysfunction at the time of screening: ALT \> 5 times the upper normal range. 9. Patients with clinically significant renal dysfunction at the time of screening: serum creatinine \> 300 µmol/L 10. Any condition, in the opinion of the investigator, that the treatment may pose a health risk to the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of FMT donors at inducing UC remission | 9 weeks | Suitability of FMT donors at inducing remission in active UC (remission defined as a Mayo score (7) \< 3 with an endoscopic Mayo score = 0 at the end of 8 weeks of FMT). |
| Efficacy of FMT at maintaining remission in UC | 3 years | Maintenance of remission of UC after three years in those who achieve initial remission with FMT. This is defined as no relapse over three years that requires any medical therapy other than more intense FMT therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of FMT at improving Quality of life | 9 weeks and 3 years | Improvement in quality of life from baseline measured by EQ5D |
| Adverse effects of FMT | 3 years | Adverse effects associated with FMT therapy |
| Efficacy of FMT at in inducing histological remission in active UC | 9 weeks | Histological remission with no active inflammation on rectal and sigmoid biopsies |
| Mucosal microbiota predicting FMT success | 9 weeks | Comparison of mucosal microbiota evaluated by 16s RNA and metagenomics in those achieving remission with FMT versus those that are not successful |
| Stool microbiota predicting FMT success | 9 weeks | Comparison of stool microbiota evaluated by 16s RNA and metagenomics in those achieving remission with FMT versus those that are not successful |
| Efficacy of FMT at relieving PRO2 symptoms | 9 weeks | A score of zero on the first two questions of the Mayo Score |
Countries
Canada
Contacts
Primary ContactMelanie A Wolfe, CCRP
Backup ContactAida Fernandes, MBA
Outcome results
None listed